BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth

4 days ago 14

MarketBeat

Wed, August 12, 2026 astatine 9:05 AM CDT 5 min read

Can BioMarin Stock Live Up to Wall Street's High Expectations?

BioMarin Pharmaceutical (NASDAQ:BMRN) outlined its maturation strategy, integration plans for Amicus Therapeutics and pipeline priorities during a Canaccord treatment with Chief Financial Officer Brian Mueller.

Mueller described BioMarin arsenic 1 of the largest rare-disease-focused biopharmaceutical companies, with much than 25 years of operating history, six first-in-disease medicines and 9 approved therapies. The institution operates successful much than 80 countries and expects gross approaching $4 cardinal this year, helium said.

→ SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat

3 Oversold Stocks with Big RSI Rebound Potential

The company's strategy centers connected genetically defined uncommon diseases, wherever BioMarin seeks to place the underlying familial origin of a information and make precision medicines targeted astatine that cause. Mueller said that attack tin enactment smaller objective studies, regulatory incentives and beardown engagement with diligent advocacy communities.

Quarterly Performance and Amicus Integration

BioMarin reported astir $1 cardinal successful second-quarter revenue, representing 20% year-over-year growth, Mueller said. The institution raised total-revenue guidance to a scope of $3.875 cardinal to $3.925 cardinal and raised non-GAAP earnings-per-share guidance to $4.90 to $5.10.

→ AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be

Are Gene Therapy Stocks The Market's Next Big Winners?

During the quarter, BioMarin completed its acquisition of Amicus Therapeutics, adding 2 commercialized rare-disease products: Galafold for Fabry illness and Pombiliti and Opfolda for Pompe disease. Mueller characterized the products arsenic high-growth assets that tin payment from BioMarin's larger planetary infrastructure.

BioMarin estimates highest gross of $1.4 cardinal for Galafold and $1.2 cardinal for Pombiliti and Opfolda, with those opportunities expected successful the mid- to precocious 2030s, respectively. The institution besides expects to recognize synergies adjacent to astir 50% of Amicus' bequest operating-cost base, chiefly done wide and administrative expenses and different enactment functions.

→ 3 Dividend Champion Utilities for a Market That Can't Sit Still

Mueller said BioMarin is preserving and investing successful the acquired income and selling enactment alternatively than pursuing assertive commercialized outgo reductions. "These products are successful their high-growth phase," helium said, adding that maintaining customer-facing capabilities is important to sustaining growth.

Read Entire Article